Tatyana V. Masyuk, Anatoliy I. Masyuk, Maria Lorenzo Pisarello, Brynn N. Howard, Bing Q. Huang, Pui‐Yuen Lee, Xavier Fung, Eduard Sergienko, Robert J. Ardecky, Thomas D.Y. Chung, Anthony B. Pinkerton, Nicholas F. LaRusso – 23 May 2017 – Hepatic cystogenesis in polycystic liver disease is associated with increased levels of cyclic adenosine monophosphate (cAMP) in cholangiocytes lining liver cysts. Takeda G protein receptor 5 (TGR5), a G protein–coupled bile acid receptor, is linked to cAMP and expressed in cholangiocytes.

Marina Serper, Michael S. Wolf – 23 May 2017

Emmanuel A. Tsochatzis, Jaime Bosch – 22 May 2017

Stefan Wirth, Philip Rosenthal, Regino P. Gonzalez‐Peralta, Maureen M. Jonas, William F. Balistreri, Chuan‐Hao Lin, Winita Hardikar, Kathryn Kersey, Benedetta Massetto, Bittoo Kanwar, Diana M. Brainard, Jiang Shao, Evguenia Svarovskaia, Brian Kirby, Ronen Arnon, Karen F. Murray, Kathleen B. Schwarz – 22 May 2017 – Children with chronic hepatitis C virus infection have limited treatment options. We evaluated the all‐oral combination of sofosbuvir and ribavirin in adolescents aged 12‐17 with hepatitis C virus genotype 2 or 3 (ClinicalTrials.gov NCT02175758).

Tracey G. Simon, Uri Kartoun, Hui Zheng, Andrew T. Chan, Raymond T. Chung, Stanley Shaw, Kathleen E. Corey – 22 May 2017 – Cardiovascular disease (CVD) is the leading cause of mortality among adults with nonalcoholic fatty liver disease (NAFLD); however, accurate tools for identifying NAFLD patients at highest CVD risk are lacking. Using a validated algorithm, we identified a retrospective cohort of 914 NAFLD patients without known CVD. Fibrosis severity was estimated using the fibrosis‐4 index.

Eon Jeong Nam, Kazutaka Hayashida, Rafael S. Aquino, John R. Couchman, Rosemary A. Kozar, Jian Liu, Pyong Woo Park – 22 May 2017 – Accidental or intentional misuse of acetaminophen (APAP) is the leading cause of acute liver failure in the Western world. Although mechanisms that trigger APAP‐induced liver injury (AILI) are well known, those that halt the progression of APAP liver disease and facilitate liver recovery are less understood.

Sofia R. Bartlett, Jason Grebely, Auda A. Eltahla, Jacqueline D. Reeves, Anita Y.M. Howe, Veronica Miller, Francesca Ceccherini‐Silberstein, Rowena A. Bull, Mark W. Douglas, Gregory J. Dore, Patrick Harrington, Andrew R. Lloyd, Brendan Jacka, Gail V. Matthews, Gary P. Wang, Jean‐Michel Pawlotsky, Jordan J. Feld, Janke Schinkel, Federico Garcia, Johan Lennerstrand, Tanya L. Applegate – 22 May 2017 – The significance of the clinical impact of direct‐acting antiviral (DAA) resistance‐associated substitutions (RASs) in hepatitis C virus (HCV) on treatment failure is unclear.

Christian Toso, Hugo Pinto Marques, Axel Andres, Francisco Castro Sousa, René Adam, Antonio Kalil, Pierre‐Alain Clavien, Emanuel Furtado, Eduardo Barroso, Henri Bismuth, on behalf of the Compagnons Hépato‐Biliaires Group – 22 May 2017

Alberto Zanetto, Sarah Shalaby, Alessandro Vitale, Claudia Mescoli, Alberto Ferrarese, Martina Gambato, Enrica Franceschet, Giacomo Germani, Marco Senzolo, Antonietta Romano, Paolo Angeli, Massimo Rugge, Fabio Farinati, Daniel M. Forton, Umberto Cillo, Patrizia Burra, Francesco Paolo Russo – 22 May 2017 – Concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following direct‐acting antiviral (DAA) therapy in patients with cirrhosis with a prior complete oncological response have been raised.

Vasantha L. Kolachala, Sirish Palle, Ming Shen, Alayna Feng, Dmitry Shayakhmetov, Nitika A. Gupta – 20 May 2017 – Steatotic liver responds with increased hepatocellular injury when exposed to an ischemic‐reperfusion insult. Increasing evidence supports the role of immune cells as key mediators of this injury in a normal (lean) state, but data about their role in a steatotic liver are practically nonexistent. The objective of the current study was to delineate the contribution of specific phenotypes of T cells and adhesion molecules in exacerbated cell death in steatotic liver injury.